$110.22
+8.21 (+8.05%)
Performance
1D
—
1W
—
1M
—
3M
+7.79%
6M
+111.68%
1Y
+955.75%
YTD
+9.62%
Open$103.56
Previous Close$102.01
Day High$110.61
Day Low$103.56
52W High$120.32
52W Low$7.58
Volume—
Avg Volume687.1K
Market Cap5.23B
P/E Ratio—
EPS$-3.67
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$105.59
Above
SMA 200
$59.11
Above
RSI (14)
39.6
Neutral
Trend
Golden Cross
Bullish
Analyst Ratings
Strong Buy
17 analysts
Price Target
-76.8% upside
Current
$110.22
$110.22
Target
$25.56
$25.56
$16.07
$25.56 avg
$38.64
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 856.50M | 842.65M | 828.36M |
| Net Income | -244,490,059 | -213,463,076 | -182,555,570 |
| Profit Margin | -28.6% | -25.3% | -22.0% |
| EBITDA | -292,781,484 | -259,398,727 | -297,826,578 |
| Free Cash Flow | -124,649,561 | -156,876,378 | -179,431,543 |
| Rev Growth | +6.2% | -3.6% | +12.6% |
| Debt/Equity | 1.11 | 1.11 | 1.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |